Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis
European Journal of Cancer · 2024
DOI: 10.1016/j.ejca.2024.113977 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Journal of Cancer, 2024. Verfasst von Michael Untch und 12 weiteren Autor:innen. Beteiligte Einrichtung: Interdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin, Germany. Electronic address: michael.untch@helios-gesundheit.de. Hauptthemen laut MEDLINE: Breast Neoplasms. Die Arbeit wurde bisher 18-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: Novartis Pharmaceuticals Corporation.
Abstract (Originalsprache)
BACKGROUND: Overall survival (OS) is a universally accepted measure of clinical benefit; however, prolonged follow-up is needed to observe sufficient events. Disease-free survival (DFS) has been widely adopted as a primary endpoint for early breast cancer (EBC) trials, as follow-up is comparatively shorter. Here, we present an analysis evaluating DFS as a surrogate for OS for adjuvant treatment of hormone receptor-positive/human epidermal growth factor receptor 2-negative (HR+/HER2-) EBC. METHODS: A systematic literature review which included randomized controlled trials (RCTs) with ≥80% of adult patients with HR+/HER2- EBC was conducted. The RCTs evaluated various systemic therapeutic categories; key inclusion criteria included reporting of DFS and OS hazard ratios (HRs) and mature OS data. Spearman rank correlation and weighted linear regression analyses evaluated DFS and OS HR correlation. A scenario analysis tested base-case analysis robustness, and a parallel analysis using patient-level data was conducted. RESULTS: The base case (N = 14 RCTs) showed an unweighted Spearman coefficient of 0.81 between OS and DFS (weighted: 0.81), with 84% of the variability in OS explained by DFS differences (R2 from weighted regression). The surrogate threshold effect (Burzykowski T, Buyse M. Pharm Stat. 2006;5:173-186) was 0.82 for DFS/OS HR. Scenario analysis (n = 9 RCTs), which excluded chemotherapy trials, and patient-level analysis using FACE trial data were consistent with the base-case analysis. CONCLUSIONS: These analyses support DFS as a reliable surrogate endpoint for OS in adjuvant HR+/HER2- EBC trials. Using DFS as a surrogate measure will permit timelier access to novel treatments for patients with HR+/HER2- EBC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Interdisciplinary Breast Cancer Center, Helios Klinikum Berlin-Buch, Berlin, Germany. Electronic address: michael.untch@helios-gesundheit.de.
- Centre Léon Bérard, Lyon, France.
- Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
- International Breast Cancer Center (IBCC), Grupo Quiron, Madrid & Barcelona, Spain.
- Practice for Hematology and Internal Oncology, Velbert, Germany.
- Edinburgh Cancer Research Centre, University of Edinburgh, Edinburgh, UK.
Förderung
- Novartis Pharmaceuticals Corporation
Zitieren
APA
Untch, M., Pérol, D., Mayer, E. L., Cortes, J., Nusch, A., Cameron, D., Barrios, C., Delea, T., Danyliv, A., Mishra, N., Gupta, R., Pathak, P., & Fasching, P. A. (2024). Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2024.113977
Vancouver
Untch M, Pérol D, Mayer EL, Cortes J, Nusch A, Cameron D, et al. Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis. European Journal of Cancer. 2024. doi:10.1016/j.ejca.2024.113977
BibTeX
@article{Untch2024,
author = {Untch, Michael and Pérol, David and Mayer, Erica L and Cortes, Javier and Nusch, Arnd and Cameron, David and Barrios, Carlos and Delea, Thomas and Danyliv, Andrii and Mishra, Namita and Gupta, Rhea and Pathak, Purnima and Fasching, Peter A},
title = {Disease-free survival as a surrogate for overall survival in HR+/HER2– early breast cancer: A correlation analysis},
journal = {European Journal of Cancer},
year = {2024},
doi = {10.1016/j.ejca.2024.113977}
}
EUVIMED